Cash-poor Prima plans for agreements
20 August, 2004 by Melissa TrudingerDespite capital raisings and exercise of options totalling $7.3 million during the year, Prima Biomed (ASX: PRR) is down to a cash balance of $2.8 million after posting a net loss of $4.9 million for the 2003-2004 financial year.
Ventracor posts $16m loss
19 August, 2004 by Melissa TrudingerVentracor (ASX: VCR) yesterday posted an AUD$15.9 million net loss for the 2003-2004 financial year, up 70 per cent from last year's $9.4 million.
Australia lagging as GM industry grows
19 August, 2004 by Graeme O'NeillOne of the founders of Australia’s leading private wheat-breeding company has delivered a bleak prognosis for the commercial future of GM crops in Australia.
How to surf the GM-testing wave
18 August, 2004 by Graeme O'NeillIf there’s money in muck, there’s also moolah in mania, according to molecular geneticist Dr Roland Toder, who built the Freiburg-based biotech company GeneScan Europe into the world’s leading gene-testing company for food and food ingredients.
Biota moves US research to Australia
18 August, 2004 by Melissa TrudingerBiota (ASX: BTA) will relocate its US research operations to its new facilities in Melbourne in a bid to save costs.
Chemeq confirms details of $50m capital raising
18 August, 2004 by Melissa TrudingerChemeq (ASX: CMQ) has confirmed that its capital raising will include a placement of around AUD$10 million to institutions and sophisticated investors, as well as an underwritten rights offer of around $40 million to existing shareholders.
Proteome Systems gears up for September float
17 August, 2004 by Graeme O'NeillSydney-based proteomics pioneer Proteome Systems lodged a long-awaited prospectus for its initial public offering on the ASX with the Australian Securities and Investment Commission today.
Tissue Therapies' Upton wins award
17 August, 2004 by Melissa Trudinger\Tissue Therapies (ASX: TIS) founder and chief scientist Dr Zee Upton has won the research scientist category for the Smart Women - Smart State awards in Queensland for her work in the area of wound healing and cell culture technologies.
Canada’s agbiotech nursery gives teething lessons
16 August, 2004 by Graeme O'NeillAustralasia’s venture capital-starved biotechnology industries probably need a fairy godmother like Canada’s Foragen Technologies Management.
FDA rejects Cyberonics device, contradicts panel
13 August, 2004 by Staff WritersThe US Food and Drug Administration has refused to approve a pacemaker-like device made by Houston-based Cyberonics to treat depression rejecting the advice of its own panel of experts.
Ag genomics centre heralds toxicity discoveries
13 August, 2004 by Graeme O'NeillTwo years after it was established, the NSW Agricultural Genomics Centre is showing its mettle, announcing the discovery of several DNA markers for genes conferring tolerance to aluminium toxicity.
Xenome CEO steps down as focus moves to US
13 August, 2004 by Melissa TrudingerXenome CEO Dr Tony Evans has stepped down as the company prepares to move into a new phase of development and activity with a focus on opportunities in the US.
UK GPs to test for asthma using Pharmaxis’ Aridol
12 August, 2004 by Renate KrelleHaving recently completed the Phase III clinical trials for its patented asthma prognostic, Aridol, Sydney-based Pharmaxis (ASX: PXS) today announced that the first patients had been enrolled in a major UK clinical study.
Panbio gets FDA approval for second-generation West Nile test
12 August, 2004 by Melissa TrudingerPanbio (ASX:PBO) has received approval from the FDA for an improved diagnostic immunoassay for West Nile Virus (WNV). The new test, which has increased specificity and sensitivity and is easier to use, comes a year after the company received approval for the first WNV test on the market.
Biota wins access to GSK documents
11 August, 2004 by Melissa TrudingerAn affidavit filed on behalf of Biota (ASX: BTA) in the Victorian Supreme Court this week has shown that the amount of money spent by GlaxoSmithKline in promoting Biota's drug Relenza in major markets dropped by 80 per cent in the second flu season after the drug was approved.
